Brii Biosciences Limited (BRIBF)
OTCMKTS
· Delayed Price · Currency is USD
0.126
0.00 (0.00%)
At close: Jul 8, 2024
Brii Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -265.45 | -174.83 | -484.31 | -4,164 | -1,190 | -521.03 |
| Depreciation & Amortization | 13.2 | 15.67 | 17.03 | 17.26 | 14.21 | 7.49 |
| Asset Writedown & Restructuring Costs | 5.43 | 5.43 | - | - | - | - |
| Loss (Gain) From Sale of Investments | -136.24 | -136.24 | -31.69 | -44.8 | 15.02 | -5.3 |
| Stock-Based Compensation | 64.22 | 64.22 | 77.93 | 79.37 | 29.48 | 23.38 |
| Other Operating Activities | -26.47 | -247.54 | 1.75 | 3,566 | 255.72 | 402.55 |
| Change in Accounts Payable | -81.46 | -81.46 | -58.14 | -286.62 | 477.59 | 7.37 |
| Change in Unearned Revenue | -6.13 | -6.13 | -3.21 | -21.94 | 17.88 | 21.92 |
| Change in Other Net Operating Assets | -33.14 | -33.14 | -15.65 | -25.18 | -24.02 | -3.66 |
| Operating Cash Flow | -466.04 | -594.01 | -496.28 | -879.46 | -403.72 | -67.28 |
| Capital Expenditures | -0.77 | - | - | -1.03 | - | -24.15 |
| Sale (Purchase) of Intangibles | -49.61 | -49.61 | -139.29 | - | - | - |
| Investment in Securities | 606.65 | -225.92 | -1,333 | -479.65 | -44.61 | -71.56 |
| Other Investing Activities | 86.69 | 171.17 | 38.65 | 4.92 | 0.96 | 2.92 |
| Investing Cash Flow | 642.97 | -104.35 | -1,433 | -475.76 | -43.65 | -92.78 |
| Long-Term Debt Repaid | - | -9.5 | -8.96 | -9.75 | -6.79 | -5.2 |
| Net Debt Issued (Repaid) | -8.32 | -9.5 | -8.96 | -9.75 | -6.79 | -5.2 |
| Issuance of Common Stock | 0.09 | 0.18 | 7.45 | 2,325 | 0.14 | - |
| Repurchase of Common Stock | -1.16 | -1.16 | -0.68 | - | - | - |
| Other Financing Activities | -1.23 | -0.49 | -0.85 | -87.81 | -4.74 | -1.15 |
| Financing Cash Flow | -10.62 | -10.98 | -3.04 | 3,230 | 657 | 518.35 |
| Foreign Exchange Rate Adjustments | 2.45 | 8.42 | 267.97 | -54.79 | -55.03 | 0.95 |
| Net Cash Flow | 168.76 | -700.92 | -1,665 | 1,820 | 154.61 | 359.24 |
| Free Cash Flow | -466.81 | -594.01 | -496.28 | -880.49 | -403.72 | -91.42 |
| Free Cash Flow Margin | -1216.27% | -1054.67% | -405.86% | -951.44% | -491.03% | -452.68% |
| Free Cash Flow Per Share | -0.64 | -0.82 | -0.69 | -2.01 | -2.11 | -0.51 |
| Cash Interest Paid | 1.23 | 0.49 | 0.85 | 1.18 | 1.67 | 1.15 |
| Levered Free Cash Flow | -412.1 | -446.87 | -438.46 | -603.47 | -37.34 | - |
| Unlevered Free Cash Flow | -411.33 | -446.56 | -437.93 | -602.74 | -36.3 | - |
| Change in Net Working Capital | 100.17 | 139.5 | 72.45 | 316.79 | -480.62 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.